Iovance Biotherapeutics, Inc. - IOVA STOCK NEWS

Iovance Biotherapeutics announced the grant of 117,000 inducement stock options to 13 new non-executive employees as part of its 2021 Inducement Plan. The options were priced at $14.04, the closing stock price on January 21, 2022. Each option vests over three years, with one-third vesting on the first anniversary of the employee's start date and the remainder in quarterly installments. This action aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Iovance's commitment to attract and retain talent in the field of cancer immunotherapy.

Iovance Biotherapeutics (NASDAQ: IOVA) announced the appointment of Dr. Raj K. Puri as Executive VP of Regulatory Strategy and Translational Medicine, effective Q1 2022. Dr. Puri brings over 33 years of FDA experience, notably leading the Division of Cellular and Gene Therapies. His expertise includes evaluating advanced therapies like T cell immunotherapy and cancer vaccines. Interim CEO Frederick G. Vogt expressed excitement about Dr. Puri's role in enhancing clinical and preclinical programs, contributing significantly to Iovance's mission of improving patient care through accessible T cell-based therapies.

Iovance Biotherapeutics announced successful manufacturing of tumor-infiltrating lymphocyte (TIL) therapy from cryopreserved tumor samples shipped from Australia. This innovation may address shipment challenges and enhance global access to TIL therapy. The company will present findings at the upcoming Tandem Meetings from February 2-6, 2022, in Salt Lake City, Utah. Two key abstracts will be presented, including results on ex vivo expansion of TILs and their treatment with decitabine. Iovance aims to lead in developing TIL therapies for cancer, particularly lifileucel for metastatic melanoma.

Iovance Biotherapeutics (NASDAQ: IOVA) announced that Fred Vogt, Interim CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The event will feature a live and archived webcast available on their website. Iovance is focused on developing T cell-based immunotherapies, with a lead candidate, lifileucel, showing promise for treating metastatic melanoma. The company emphasizes innovation in cell therapy aimed at improving cancer care.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) granted inducement stock options for 107,900 shares to eleven new non-executive employees on December 16, 2021. This grant is part of Iovance's 2021 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $17.80, equivalent to the closing price on the grant date. Each option vests over three years, with one-third vesting after one year and the rest quarterly thereafter, contingent on continued employment.

Iovance Biotherapeutics (NASDAQ: IOVA) recently announced its participation in key December conferences focused on cancer immunotherapy. The company will engage in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 7 at 1:40 p.m. ET. Additionally, Iovance will present an on-demand poster at the ESMO Immuno-Oncology Annual Meeting from December 8-11, highlighting AKT inhibition's impact on TIL expansion. At the American Society of Hematology Annual Meeting from December 11-14, a poster will detail the Phase 1/2 study of IOV-2001 for chronic lymphocytic leukemia.

Iovance Biotherapeutics (NASDAQ: IOVA) announced the grant of inducement stock options for 168,575 shares to seven new non-executive employees on November 18, 2021. The options, part of the 2021 Inducement Plan, have an exercise price of $19.05, equal to the closing stock price on the grant date. Each option vests over three years, with one-third vesting on the first anniversary and the remainder in quarterly installments. This move is aligned with Iovance's focus on developing T cell-based cancer immunotherapies, notably its lead candidate lifileucel for metastatic melanoma.

Iovance Biotherapeutics (NASDAQ: IOVA) reported promising clinical data on its lifileucel TIL cell therapy combined with pembrolizumab, presented at the SITC Annual Meeting. The overall response rates were 57.1% in cervical cancer, 60.0% in melanoma, and 38.9% in head and neck cancer. Notably, a 30% complete response rate was observed in melanoma patients. The findings support continued investigation of TIL therapy as a treatment option. A conference call is scheduled for November 13, 2021, to discuss these results further.

Iovance Biotherapeutics has announced new clinical data for its TIL therapy, LN-145, showcasing a 21.4% overall response rate in heavily pre-treated patients with metastatic non-small cell lung cancer (mNSCLC). The therapy demonstrated effectiveness even in patients resistant to previous treatments. The clinical trial results were presented during the SITC Annual Meeting in Washington, D.C. and suggest continued investigation of LN-145 in upcoming studies. The company emphasizes the significance of these findings in addressing unmet needs in second-line mNSCLC treatment.